RobertJMotzerMD

Genitourinary Oncology, Hematologic Oncology

Attending Physician, Memorial Sloan-Kettering Cancer Center and Professor of Medicine, Cornell University-Weill Medical College

Request Appointment

Overview of Dr. Motzer

Dr. Robert Motzer is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of Michigan Medical School and has been in practice 36 years. Dr. Motzer accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 64 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(424) 336-9659

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1981 - 1984
University of Michigan Medical SchoolClass of 1981

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 1983 - 2026
NJ State Medical License 2019 - 2025
MI State Medical License 1987 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2003-2014
America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
New York Magazine: Top Doctors Castle Connolly, 2002-2008
Join now to see all

Clinical Trials

Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin Start of enrollment: 1994 Jan 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Start of enrollment: 1994 Sep 01
Completed
Phase 3
Interferon Alfa in Treating Patients With Advanced Kidney Cancer Start of enrollment: 1998 May 01
Completed
Phase 1, Phase 2
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 2
Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin Start of enrollment: 2000 Feb 01
Completed
Phase 2
ZD 1839 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2001 Jan 01
Completed
Phase 2
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Dec 01
Completed
Phase 1
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2002 Apr 01
Completed
Phase 2
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2002 Apr 01
Completed
Phase 1
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors Start of enrollment: 2004 Apr 01
Terminated
Phase 3
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 Start of enrollment: 2005 Jul 06
Completed
Phase 1
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients Start of enrollment: 2006 Mar 01
Completed
Phase 1
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2007 Mar 01
Completed
Phase 2
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors Start of enrollment: 2007 Mar 01
Completed
Phase 2
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Start of enrollment: 2009 Dec 01
Completed
Phase 3
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). Start of enrollment: 2010 Mar 01
Completed
Phase 3
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2010 Aug 01
Completed
Phase 1
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) Start of enrollment: 2011 Jul 01
Completed
Phase 2
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Start of enrollment: 2011 Oct 01
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].
Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, Maria I Carlo, Andrea Knezevic
European Urology. 2025-01-01
Management of Kidney Cancer Relapse to Adjuvant Pembrolizumab: Early Insights and Questions for a Newly Emerging Space.
Martin H Voss, Robert J Motzer
European Urology. 2024-12-01
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.
Sahil D Doshi, Andrea Knezevic, Carlene Gonzalez, Patricia Fischer, Robert Goodman
Clinical Genitourinary Cancer. 2024-11-13

Journal Articles

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Safety, Therapy Management, and Patient-Reported Outcomes in the S-TRAC Trial
Robert Motzer, MD, Annals of Oncology
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature
Checkpoint Inhibitors and Other Novel Immunotherapies for Advanced Renal Cell Carcinoma
Martin H Voss, Robert J Motzer, Nature
Join now to see all

Lectures

Trial Results Establish Clinical Benefit of RAD001 in Advanced Renal Cell Carcinoma
2008 Annual Meeting, Chicago, Illinois, USA
Trial Results Establish Clinical Benefit of RAD001 in Advanced Renal Cell Carcinoma
American Society of Clinical Oncology, 2008 Annual Meeting, Chicago, Illinois, USA

Press Mentions

Final Analysis of JAVELIN Renal 101 Shows Long-Term Efficacy of Avelumab plus AxitinibJune 10th, 2024
MSK Research Highlights, February 23, 2023February 23rd, 2023
Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCCSeptember 15th, 2022
Join now to see all

Grant Support

Molecular Basis Of Renal Cell Carcinoma Response To Su11428National Cancer Institute2007–2011
Clinical Trials And Mentoring In Oncology ResearchNational Cancer Institute1999–2003

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment